Latest Content

FDA approves Axsome’s AXS-05 for Alzheimer’s agitation, backed by multiple trials.

Clinicians explore neuroscience-guided off-label prescribing.

DSM-6 forces psychiatry to choose: sharper science or softer labels. Explore why validity, biomarkers, and hierarchy matter for credibility.

The triple-blinded EPISODE trial with active placebo and 4 dosing regimens yielded mixed results, reflecting the challenge of discerning psilocybin effect and distinguishing between enlightenment and expectation.

New US patent backs Denovo’s ANK3 biomarker guiding DB104 for treatment‑resistant depression, highlighting promising efficacy in selected patients.

Lifestyle medicine pillars help reshape depression and anxiety treatment in psychiatry.

AI video screening spots early tardive dyskinesia signs, prompting clinical follow-up and treatment.

Read our exclusive interview with Daniel R. Karlin, MD, MA, on the latest executive order, DT120 for the treatment of mental health disorders, and more.

Spot ICU delirium early with MD‑MOSAIC—an exam for ventilated patients that sharpens diagnosis, prevents harm, and improves outcomes.

Study links schizophrenia’s earlier onset to higher genomic deletion CNV burden, showing future potential for personalized care.

Round on the latest news in psychiatry from the last week.

Adial seeks FDA priority voucher to speed AD04 review, a biomarker-guided therapy aiming to curb heavy drinking in alcohol use disorder.

FDA expands Caplyta label to prevent schizophrenia relapse, cutting risk 63% and showing weight-neutral tolerability for sustained long-term stability.